The biotech sector has always held a special appeal for risk-tolerant investors. While these companies face high overhead in the form of towering R&D costs and long lead times for bringing new ...

This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary ...

Biotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to ...

As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies ...

Immunovant reports clinically meaningful trial results for its lead drug candidate. That’s good news for Roivant Sciences.

ADMA Biologics develops plasma-derived therapies for immune deficiencies and infectious diseases, leveraging a vertically integrated model.

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation.

In this article, we will discuss: 8 Most Promising Biotech Stocks to Buy Now. On January 14, Reuters reported that investors ...

Silexion Therapeutics (Nasdaq: SLXN) shares surge over 72% on Phase 2/3 SIL204 trial progress for KRAS-driven pancreatic ...

State Street SPDR S&P Biotech ETF (XBI) gained +40.32% over the past year and equally weights roughly 145 stocks to provide exposure to smaller biotech companies. iShares Biotechnology ETF (IBB) ...

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...